Low Expression of Excision Repair Cross-complementation Group-1 Protein Predicts Better Outcome in Patients with Locally Advanced Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy

Sun J.M. , Ahn M.J. , Park M.J. , Lee H.Y. , Ahn J.S. , Lee S. , Kang G. , Han J. , Son Y.I. , Baek C.H. , Ahn Y.C. , Park K. : Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys, 80: 655–660, 2011.

Al-Sarraf M. , LeBlanc M. , Giri P.G. , Fu K.K. , Cooper J. , Vuong T. , Forastiere A.A. , Adams G. , Sakr W.A. , Schuller D.E. , Ensley J.F. : Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol, 16: 1310–1317, 1998.

Lin J.C. , Jan J.S. , Hsu C.Y. , Liang W.M. , Jiang R.S. , Wang W.Y. : Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol, 21: 631–637, 2003.

Wee J. , Tan E.H. , Tai B.C. , Wong H.B. , Leong S.S. , Tan T. , Chua E.T. , Yang E. , Lee K.M. , Fong K.W. , Tan H.S. , Lee K.S. , Loong S. , Sethi V. , Chua E.J. , Machin D. : Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol, 23: 6730–6738, 2005.

Qin DX1 , Hu Y.H. , Yan J.H. , Xu G.Z. , Cai W.M. , Wu X.L. , Cao D.X. , Gu X.Z. : Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer, 61: 1117–1124, 1998.

Zhang EP1 , Lian P.G. , Cai K.L. , Chen Y.F. , Cai M.D. , Zheng X.F. , Guang X.X. : Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1302 patients. Int J Radiat Oncol Biol Phys, 16: 301–305, 1989.

Chan A.T. , Leung S.F. , Ngan R.K. , Teo P.M. , Lau W.H. , Kwan W.H. , Hui E.P. , Yiu H.Y. , Yeo W. , Cheung F.Y. , Yu K.H. , Chiu K.W. , Chan D.T. , Mok T.S. , Yau S. , Yuen K.T. , Mo F.K. , Lai M.M. , Ma B.B. , Kam M.K. , Leung T.W. , Johnson P.J. , Choi P.H. , Zee B.C. : Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst, 97: 536–539, 2005.

Olaussen K.A. , Dunant A. , Fouret P. , Brambilla E. , André F. , Haddad V. , Taranchon E. , Filipits M. , Pirker R. , Popper H.H. , Stahel R. , Sabatier L. , Pignon J.P. , Tursz T. , Le Chevalier T. , Soria J.C. ; IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355: 983–991, 2006.

Darcy K.M. , Tian C. , Reed E. : A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res, 67: 4474–4481, 2007.

Kwon H.C. , Roh M.S. , Oh S.Y. , Kim S.H. , Kim M.C. , Kim J.S. , Kim H.J. : Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 18: 504–509, 2007.

Stoehlmacher J. , Park D.J. , Zhang W. , Yang D. , Groshen S. , Zahedy S. , Lenz H.J. : A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91: 344–354, 2004.

Kim M.K. , Cho K.J. , Kwon G.Y. , Park S.I. , Kim Y.H. , Kim J.H. , Song H.Y. , Shin J.H. , Jung H.Y. , Lee G.H. , Choi K.D. , Kim S.B. : ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer, 44: 54–60, 2008.

Huang P.Y. , Li Y. , Mai H.Q. , Luo R.Z. , Cai Y.C. , Zhang L. : Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncol, 48: 964–968, 2012.

Sun J.M. , Sung J.Y. , Park S.H. , Kwon G.Y. , Jeong B.C. , Seo S.I. , Jeon S.S. , Lee H.M. , Jo J. , Choi H.Y. , Lim H.Y. : ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer, 12: 187, 2012.

Handra-Luca A. , Hernandez J. , Mountzios G. , Taranchon E. : Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatinbased induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res, 13: 3855–3859, 2007.

Ceppi P. , Volante M. , Novello S. , Rapa I. , Danenberg K.D. , Danenberg P.V. , Cambieri A. , Selvaggi G. , Saviozzi S. , Calogero R. , Papotti M. , Scagliotti G.V. : ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non–small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 17: 1818–1825, 2006.

Selvakumaran M. , Pisarcik D.A. , Bao R. , Yeung A.T. , Hamilton T.C. : Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res, 63: 1311–1316, 2003.

Lord R.V. , Brabender J. , Gandara D. , Alberola V. , Camps C. , Domine M. , Cardenal F. , Sánchez J.M. , Gumerlock P.H. , Tarón M. , Sánchez J.J. , Danenberg K.D. , Danenberg P.V. , Rosell R. : Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8: 2286–2291, 2002.

Britten R.A. , Liu D. , Tessier A. , Hutchison M.J. , Murray D. : ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer, 89: 453–457, 2000.

Larminat F. , Bohr V.A. : Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res, 22: 3005–3010, 1994.

Guo W.F. , Lin R.X. , Huang J. , Zhou Z. , Yang J. , Guo G.Z. , Wang S.Q. : Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res, 164: 27–35, 2005.

Jeong J. , Hong S.J. , Ju Y.J. , Kim B.Y. , Park M.J. , Kim T.H. , Park C.I. , Choi K.Y. , Cho M.H. , Kim S.H. , Lee H. , Lee K.H. : Temporal cDNA microarray analysis of gene expression in human hepatocellular carcinoma upon radiation exposure. Oncol Rep, 15: 33–48, 2006.

Murray D. , Rosenberg E. : The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res, 364: 217–226, 1996.

Doll C.M. , Craighead P. , Diaz R. , Box A. , Shin B. , Eliasziw M. , Lees-Miller S. , Magliocco A.M. : High ERCC1 expression is associated with worse survival in patients with locally advanced cervical cancer treated with radiotherapy (RT): an evaluation of AQUA® versus conventional IHC methods. Int J Radiat Oncol Biol Phys, 72: S18–S19, 2008.

Kim M.K. , Cho K.J. , Kwon G.Y. , Park S.I. , Kim Y.H. , Kim J.H. , Song H.Y. , Shin J.H. , Jung H.Y. , Lee G.H. , Choi K.D. , Kim S.B. : ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer, 44: 54–60, 2008.

Joshi M.B. , Shirota Y. , Danenberg K.D. , Conlon D.H. , Salonga D.S. , Herndon JE 2nd , Danenberg P.V. , Harpole DH Jr : High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res, 11: 2215–2221, 2005.

Nix P. , Greenman J. , Stafford N. , Cawkwell L. : Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Ther, 2: 47–53, 2004.

Azuma K. , Sasada T. , Kawahara A. , Hattori S. , Kinoshita T. , Takamori S. , Ichiki M. , Imamura Y. , Ikeda J. , Kage M. , Kuwano M. , Aizawa H. : Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol, 64: 565–573, 2009.

Hwang I.G. , Ahn M.J. , Park B.B. , Ahn Y.C. , Han J. , Lee S. , Kim J. , Shim Y.M. , Ahn J.S. , Park K. : ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer, 113: 1379–1386, 2008.

Jun H.J. , Ahn M.J. , Kim H.S. , Yi S.Y. , Han J. , Lee S.K. , Ahn Y.C. , Jeong H.S. , Son Y.I. , Baek J.H. , Park K. : ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer, 99: 167–172, 2008.

Langendijk J.A. , Leemans C.R. , Buter J. , Berkhof J. , Slotman B.J. : The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a metaanalysis of the published literature. J Clin Oncol, 22: 4604–4612, 2004.

Baujat B. , Audry H. , Bourhis J. , Chan A.T. , Onat H. , Chua D.T. , Kwong D.L. , Al-Sarraf M. , Chi K.H. , Hareyama M. , Leung S.F. , Thephamongkhol K. , Pignon J.P. ; MAC-NPC Collaborative Group: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys, 64: 47–56, 2006.

Chua D.T. , Nicholls J.M. , Sham J.S. , Au G.K. : Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys, 59: 11–20, 2004.

Lo Y.M. , Chan L.Y. , Lo K.W. , Leung S.F. , Zhang J. , Chan A.T. , Lee J.C. , Hjelm N.M. , Johnson P.J. , Huang D.P. : Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 59: 1188–1191, 1999.

Lo Y.M. , Chan A.T. , Chan L.Y. , Leung S.F. , Lam C.W. , Huang D.P. , Johnson P.J. : Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res, 60: 6878–6881, 2000.